• First Remplir surgical case successfully completed within the U.S. Department of Defense (DoD) / Veterans Affairs (VA) hospital network
• Rapid conversion of approval into clinical use following DoD / VA access announcement
• Demonstrates early surgeon engagement and effectiveness of Orthocell's U.S. commercial and distributor footprint

Orthocell Limited (ASX: OCC) is pleased to announce that the first surgical case using Remplir has been successfully completed within the U.S. Department of Defense (DoD) / Veterans Affairs (VA) hospital network, shortly after the Company announced approval to supply Remplir into these hospital systems. This milestone marks the first clinical use of Remplir within the DoD / VA network and represents an important step in Orthocell's U.S. commercialisation strategy, demonstrating the Company's ability to rapidly translate regulatory and procurement approvals into real-world surgical adoption and revenue generation. The surgery was conducted at a military base hospital in Ohio. As announced on 15 April 2026, Orthocell secured approval for Remplir to be supplied across the U.S. Department of Defense and Veterans Affairs hospital networks, providing access to approximately 51 DoD military hospitals and 170 VA medical centres nationwide. The rapid completion of a first surgical case highlights early engagement from surgeons within these systems and reinforces the strength of Orthocell's existing U.S. distributor footprint, which spans 17 states and supports efficient onboarding and in-theatre case support. These distributors will now support further uptake of Remplir across the DoD and VA systems as part of Orthocell's broader US commercialisation strategy.

Orthocell will continue to work closely with its U.S. distribution partners and surgeon network to support further uptake of Remplir across the DoD and VA systems as part of its broader U.S. commercialisation strategy.